Patients Views & Analysis

Views & Analysis

Patients

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.

Patients

pharmaphorum podcast Episode 263, Rebecca Guntern - Sandoz

Biosimilars & patient access independent of geographies or s...

Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.

Patients

ASCO 26: Three cancer survivors share lessons for the field

In honour of National Cancer Survivors' Day, we recount three patient testimonies and calls to action from ASCO Voices at ASCO 2026.

Patients

Clinical trials fail in recruitment

Clinical trials struggle in many areas, and significantly in recruitment.

Patients

pharmaphorum podcast Episode 262, Lee-Ann Farrell, Johnson & Johnson

Towards a healthier world: Momentum in UK health system tran...

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Lee-Ann Farrell, Head of National Programmes at Johnson & Johnson.

Patients

ASCO 26: War, disasters, policy compound cancer care challen...

A Friday ASCO session highlighted the challenges faced by cancer patients in situations of geopolitical crisis, as presenters called for more support.

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

Biosimilars & patient access independent of geographies or s...

ASCO 26: Three cancer survivors share lessons for the field

Clinical trials fail in recruitment

Towards a healthier world: Momentum in UK health system tran...

ASCO 26: War, disasters, policy compound cancer care challen...

Novartis sets sights on new oral MS drug after phase 3 wins

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks